Navigation Links
Echo Therapeutics Announces First Quarter 2013 Financial Results

PHILADELPHIA, May 10, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced financial results for the quarter ended March 31, 2013.  Echo's Quarterly Report on Form 10-Q, as filed with the SEC, will be available by visiting the Investors section of Echo's website at


Recent Corporate Highlights

  • In March, Echo was granted International Standards Organization (ISO) 13485:2003 certification of its quality system.  ISO 13485:2003 is an internationally recognized standard that prescribes consistent processes for the development, design and manufacturing of medical devices and represents an important step toward attaining European CE Mark approval.
  • Echo completed a public offering of approximately $10.6 million, after expenses, in February.  Echo also voluntarily prepaid the $3 million outstanding balance of its $20 million credit facility with Platinum-Montaur Life Sciences, LLC.
  • Echo participated in various medical and investor conferences and symposia. In January, Echo presented data during a poster session at the Society of Critical Care Medicine's (SCCM) Annual Meeting and, in February, Echo exhibited its Symphony CGM technology at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).  In January, management presented to prospective corporate partners and investors at the Noble Financial Markets' Ninth Annual Equity Conference and at the Biotech Showcase 2013 Conference.
  • Echo appointed Robert F. Doman to its Board of Directors in March.  Mr. Doman brings over 30 years of executive level, international and domestic management, business development, sales and marketing, product development and strategic planning experience with specific concentrations in medical devices and pharmaceuticals.
  • Echo announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent 8,386,027, "Skin Permeation Device for Analyte Sensing or Transdermal Drug Delivery," for the skin permeation component of the Symphony CGM System.  Echo currently holds 8 U.S. patents and at least 70 foreign patents, and has at least 25 patent applications pending in the U.S. and foreign countries.
  • "Design freeze of our Symphony CGM System and the ISO 13485 certification of our quality management system in the first quarter validated the progress we made in 2012.  We are on track to conduct our multi-center CE Mark pivotal trial and to submit our CE Technical File in the near term," commented Patrick T. Mooney , M.D., Chairman and Chief Executive Officer of Echo Therapeutics.  "With several important milestones still ahead, we look forward to increased shareholder value and commercializing Symphony in Europe later this year."

    First Quarter 2013 Financial Results Echo's net loss for the first quarter of 2013 was $7.0 million, or ($0.13) per share, compared to $3.0 million, or ($0.08) per share, for the first quarter of 2012.  Operating loss for the first quarter of 2013 was $5.5 million compared to $3.2 million for the first quarter of 2012.  Research and development expenses were $3.2 million for the first quarter of 2013 compared to $1.4 million in the prior year. Research and development expenses increased primarily as a result of greater engineering and design expenses incurred with outside contractors and personnel.  General and administration expenses were $2.3 million for the first quarter of 2013 versus $1.9 million in the prior year. The Company reported a cash balance of approximately $5.2 million as of March 31, 2013.Conference Call
Management will host a conference call today starting at 9:00 AM EDT.  To listen in and/or participate in the call, please dial (877) 317-6789 and reference the conference number 10028680.  The archived audiocast will be available for fourteen days following the call by visiting the Events section of Echo's website at

    About Echo Therapeutics
Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system.  Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care.  Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting.  Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

    Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

    For More Information:
    Christine H. Olimpio
    Director, Investor Relations and Corporate Communications
    (215) 717-4104Connect With Us:
    - Visit our website at
    - Follow us on Twitter at
    - Join us on Facebook at Therapeutics, Inc 

    Condensed Consolidated Balance Sheets   March 31,2013December 31,2012ASSETSCurrent Assets:Cash and cash equivalents

    3,747,210Cash restricted pursuant to letters of credit

    657,463407,463Deferred financing costs, current portion

    968,004968,004Prepaid expenses and other current assets

    231,17175,626Total current assets

    7,026,8895,198,303Net property and equipment (including assets under capitalized leases)

    1,678,4641,638,395Intangible assets, net of accumulated amortization

    9,625,0009,625,000Deferred financing costs, net of current portion

    3,307,3273,549,328Restricted cash, deposits and other assets

    10,56610,566Total assets

    20,021,592LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

    2,319,219Deferred revenue from licensing arrangements

    67,67190,228Capital lease obligations, current portion

    2,5912,527Derivative warrant liability

    3,904,1555,585,141Accrued expenses and other liabilities

    1,759,5371,581,448Total current liabilities

    7,233,2489,578,563Deferred revenue, note payable and capital lease obligation, net of current portion 

    90,917212,423Total liabilities

    7,324,1659,790,986CommitmentsStockholders' Equity:Convertible preferred stock, Series C & D

    30,16030,160Common stock

    602,449443,737Additional paid-in capital

    114,581,812103,658,724Accumulated deficit

    (100,890,340)(93,902,015)Total stockholders' equity

    14,324,08110,230,606Total liabilities and stockholders' equity

    20,021,592Condensed Consolidated Statements of OperationsThree Months Ended March 31,20132012Licensing revenue

    30,927Total revenues

    22,55730,927Operating Expenses:Research and development

    3,219,7231,391,645Selling, general and administrative

    2,299,4471,859,404Total operating expenses

    5,519,1703,251,049Loss from operations

    (5,496,613)(3,220,122)Other Income (Expense):Interest income (expense), net

    (3,172,698)2,809Gain on revaluation of derivative warrant liability

    1,680,986231,543Other income (expense), net

    (1,491,712)234,352Net loss

    (6,988,325)(2,985,770)Net loss per common share, basic and diluted

    (0.08)Basic and diluted weighted average common shares outstanding


    SOURCE Echo Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
    2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
    3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
    7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
    8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
    9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
    10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
    11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
    Post Your Comments:
    (Date:5/8/2017)... , May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: ... Inc. ("WRB"), a health care service center company ... WRB specializes in relationship management programs for leading ... WRB will join Envoy ... support services for manufacturers, biotech firms, and other service ...
    (Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
    (Date:5/4/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... today announced that the Company,s first quarter 2017 financial ... May 11, 2017, and that the Company will host ... PT that afternoon. Management will provide an overview of ...
    Breaking Medicine Technology:
    (Date:5/28/2017)... City, FL (PRWEB) , ... May 28, 2017 , ... ... be treated with Nerve-Express, the latest Heart Rate Variability (HRV) diagnostic test. , Nerve-Express, ... heart rate and R-R interval, indicating the state of a patient’s autonomic nervous system ...
    (Date:5/28/2017)... FL (PRWEB) , ... May 28, 2017 , ... ... of America (PPOA), is proud to announce that Sheldon K. Cho, MD, has ... interventional pain management, a specialty that concentrates on minimally invasive techniques to treat ...
    (Date:5/27/2017)... TX (PRWEB) , ... May 27, 2017 , ... Hate visiting the dentist? You should ... you'll need to take care of your teeth at home. Here are some dental tips ... after meals. Keep a small toothbrush in your work desk or a locker at school ...
    (Date:5/27/2017)... ... 27, 2017 , ... Most us are familiar with the sound of occasional ... the Osteoarthritis Initiative shows that certain people who experience consistent joint popping, grating ... give doctors the opportunity to treat patients before the problem becomes pronounced, potentially hedging ...
    (Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, ... 30th and 31st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
    Breaking Medicine News(10 mins):